Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1981 May;19(5):740–744. doi: 10.1128/aac.19.5.740

Moxalactam therapy for a wide spectrum of bacterial infections in adults.

R W Tofte, J Rotschafer, J Solliday, K B Crossley
PMCID: PMC181515  PMID: 6457555

Abstract

We evaluated the efficacy and toxicity of moxalactam during treatment of 45 documented infections in 36 patients. A majority of patients received 4.5 g of moxalactam per day. There was a good clinical response in 42 of the 45 (94%) infections, including 3 bacteremias, 20 skin and soft tissue infections, 6 gram-negative lower respiratory tract infections, 6 purulent diabetic foot ulcers, 3 wound infections, 3 urinary tract infections, and 4 miscellaneous infections (meningitis, suppurative phlebitis, peritonitis, bursitis). Previously, 11 of these patients had failed to respond to other antibiotics. Our three treatment failures were attributed to abnormal host defense in two patients and to a resistant enterococcal urinary tract infection in another. Moxalactam was tolerated well as produced minimal renal, hepatic, and hematological toxicities. The only serious adverse effect were the development of documented pseudomembranous colitis in one patient and progressive renal dysfunction in another. Acquisition of resistance among noneradicated isolates during therapy was not demonstrated.

Full text

PDF
740

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Berk S. L., McCabe W. R. Meningitis caused by gram-negative bacilli. Ann Intern Med. 1980 Aug;93(2):253–260. doi: 10.7326/0003-4819-93-2-253. [DOI] [PubMed] [Google Scholar]
  2. Fass R. J. In vitro activity of LY127935. Antimicrob Agents Chemother. 1979 Oct;16(4):503–509. doi: 10.1128/aac.16.4.503. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Fierer J., Daniel D., Davis C. The fetid foot: lower-extremity infections in patients with diabetes mellitus. Rev Infect Dis. 1979 Jan-Feb;1(1):210–217. doi: 10.1093/clinids/1.1.210. [DOI] [PubMed] [Google Scholar]
  4. Hall W. H., Opfer B. J., Gerding D. N. Comparative activities of the oxa-beta-lactam LY127935, cefotaxime, cefoperazone, cefamandole, and ticarcillin against multiply resistant gram-negative bacilli. Antimicrob Agents Chemother. 1980 Feb;17(2):273–279. doi: 10.1128/aac.17.2.273. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Landesman S. H., Corrado M. L., Cherubin C. C., Gombert M., Cleri D. Diffusion of a new beta-lactam (LY 127935) into cerebrospinal fluid. Implications for therapy of gram-negative bacillary meningitis. Am J Med. 1980 Jul;69(1):92–98. doi: 10.1016/0002-9343(80)90505-7. [DOI] [PubMed] [Google Scholar]
  6. Neu H. C., Aswapokee N., Fu K. P., Aswapokee P. Antibacterial activity of a new 1-oxa cephalosporin compared with that of other beta-lactam compounds. Antimicrob Agents Chemother. 1979 Aug;16(2):141–149. doi: 10.1128/aac.16.2.141. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Neu H. C. Cefoxitin: an overview of clinical studies in the United States. Rev Infect Dis. 1979 Jan-Feb;1(1):233–239. doi: 10.1093/clinids/1.1.233. [DOI] [PubMed] [Google Scholar]
  8. Parsons J. N., Romano J. M., Levison M. E. Pharmacology of a new 1-oxa-beta-lactam (LY127935) in normal volunteers. Antimicrob Agents Chemother. 1980 Feb;17(2):226–228. doi: 10.1128/aac.17.2.226. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Perkins R. L., Fass R. J., Warner J. F., Prior R. B., File T. M., Tight R. R., Gardner W. G., Ruiz D. E., Slama T. G. Cefamandole nafate therapy of respiratory tract, skin, and soft tissue infections in 74 patients. J Infect Dis. 1978 May;137 (Suppl):S110–S118. doi: 10.1093/infdis/137.supplement.s110. [DOI] [PubMed] [Google Scholar]
  10. Pierce A. K., Sanford J. P. Aerobic gram-negative bacillary pneumonias. Am Rev Respir Dis. 1974 Nov;110(5):647–658. doi: 10.1164/arrd.1974.110.5.647. [DOI] [PubMed] [Google Scholar]
  11. Sabath L. D., Casey J. I., Ruch P. A., Stumpf L. L., Finland M. Rapid microassay for circulating nephrotoxic antibiotics. Antimicrob Agents Chemother (Bethesda) 1970;10:83–90. doi: 10.1128/AAC.10.1.83. [DOI] [PubMed] [Google Scholar]
  12. Trager G. M., White G. W., Zimelis V. M., Panwalker A. P. LY-127935: a novel beta-lactam antibiotic with unusual antibacterial activity. Antimicrob Agents Chemother. 1979 Sep;16(3):297–300. doi: 10.1128/aac.16.3.297. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES